home > ict > winter 2020 > the impact of gdpr for health organisations
International Clinical Trials

The Impact of GDPR for Health Organisations

Privacy concerns have been growing exponentially due to the large amount of information and personal data being stored digitally today. As healthcare, pharmaceutical, and biotechnology companies move towards greater digitisation and store more and more sensitive or regulated data, the risk of cyber security incidents and information leaks increases.

The information can be anywhere, in file servers in the company, user’s computers, mobile devices, internal databases, cloud applications, etc. The productive environment of this industry is becoming connected and automated. This connectivity makes them more susceptible to attacks, and increases the need to secure more points within the lifecycle of information related to patient data.

Patient Data: Especially Valuable and Sensitive

This sector is one where the level of sensitivity of the data is higher. Not all personal data are similar, and although we can change our email address, we cannot change our medical history if it has been stolen or mishandled.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the author

Luis Ángel del Valle is CEO at SealPath and a Telecommunications Engineer from the University of the Basque Country, Spain, with more than 20 years of experience in the area of cybersecurity and communications software. He founded SealPath, a leading company in the protection and control of confidential information, to provide companies with data-centric information protection solutions that allow them to keep their sensitive data under control wherever they are, in an environment where data are increasingly mobile and the security perimeter of companies has become blurred.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Kayentis and ClinOne join forces to improve efficiency and patient experience in clinical trials

Grenoble, France, and Needham (MA), US, January 10, 2023 – Kayentis, a global provider of electronic Clinical Outcome Assessment (eCOA) and Decentralized Clinical Trial (DCT) solutions, and ClinOne, a leading provider for adaptive clinical trial experiences for patients, families and clinical sites, today announce a strategic alliance. This collaboration combines Kayentis’ expertise in clinical trial data collection with ClinOne’s best-in-class consent management and patient engagement technology. Together, they enable patients and sites to access a complete range of DCT solutions with a single point of entry for all types of trials – from traditional to fully decentralized.
More info >>

White Papers

galenIQ - The smart excipient


galenIQ combines a multitude of outstanding characteristics and is suitable for a wide range of pharmaceutical applications. galenIQ can be used as more than just a bulk excipient. It also serves as an anti-caking agent, anti-humectant agent, stabilizer or oral care and taste agent to mention just a few additional functions.
More info >>




©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement